Journal of Clinical Medicine Research, ISSN 1918-3003 print, 1918-3011 online, Open Access |

Article copyright, the authors; Journal compilation copyright, J Clin Med Res and Elmer Press Inc |

Journal website http://www.jocmr.org |

Original Article

Volume 12, Number 7, July 2020, pages 415-422

**Lymphocyte-to-C-Reactive Protein Ratio: A Novel Predictor of Adverse Outcomes in COVID-19**

Figures

Tables

NLR < 10 | NLR > 11 | Significance | LCR < 10 | LCR > 11 | Significance | |
---|---|---|---|---|---|---|

DM: diabetes mellitus; HTN: hypertension; CKD: chronic kidney disease; CAD: coronary artery disease; COPD: chronic obstructive pulmonary disease; HCQ: hydroxychloroquine; TM: tocilizumab; SD: steroid; AC: anticoagulation. | ||||||

Age | 63.6 years | 61.6 years | P = 0.71 | 62.6 years | 63.7 years | P = 0.65 |

Sex | ||||||

Men | 66 (80.50%) | 16 (19.50%) | P = 0.167 | 23 (27.70%) | 60 (72.30%) | P = 0.04 |

Women | 75 (88.20%) | 10 (11.80%) | 13 (14.90%) | 74 (85.10%) | ||

DM | ||||||

No | 92 (85.20%) | 16 (14.80%) | P = 0.716 | 23 (21.10%) | 86 (78.90%) | P = 0.974 |

Yes | 49 (83.10%) | 10 (16.90%) | 13 (21.30%) | 48 (78.70%) | ||

HTN | ||||||

No | 48 (80.00%) | 12 (20.00%) | P = 0.237 | 14 (23.30%) | 46 (76.70%) | P = 0.611 |

Yes | 93 (86.90%) | 14 (13.10%) | 22 (20.00%) | 88 (80.00%) | ||

CAD | ||||||

No | 114 (82.60%) | 24 (17.40%) | P = 0.16 | 30 (21.60%) | 109 (78.40%) | P = 0.784 |

Yes | 27 (93.10%) | 2 (6.90%) | 6 (19.40%) | 25 (80.60%) | ||

CKD | ||||||

No | 114 (83.80%) | 22 (16.20%) | P = 0.65 | 28 (20.30%) | 110 (79.70%) | P = 0.557 |

Yes | 27 (87.10%) | 4 (12.90%) | 8 (25.00%) | 24 (75.00%) | ||

COPD | ||||||

No | 119 (83.20%) | 24 (16.80%) | P = 0.29 | 32 (21.90%) | 114 (78.10%) | P = 0.56 |

Yes | 22 (91.70%) | 2 (8.30%) | 4 (16.70%) | 20 (83.30%) | ||

HCQ | ||||||

No | 27 (87.10%) | 4 (12.90%) | P = 0.65 | 8 (27.60%) | 21 (72.40%) | P = 0.354 |

Yes | 114 (83.80%) | 22 (16.20%) | 28 (19.90%) | 113 (80.10%) | ||

TM | ||||||

No | 117 (84.80%) | 21 (15.20%) | P = 0.78 | 28 (20.30%) | 110 (79.70%) | P = 0.557 |

Yes | 24 (82.80%) | 5 (17.20%) | 8 (25.00%) | 24 (75.00%) | ||

SD | ||||||

No | 115 (83.30%) | 23 (16.70%) | P = 0.39 | 32 (22.90%) | 108 (77.10%) | P = 0.247 |

Yes | 26 (89.70%) | 3 (10.30%) | 4 (13.30%) | 26 (86.70%) | ||

AC | ||||||

No | 115 (85.80%) | 19 (14.20%) | P = 0.318 | 25 (18.40%) | 111 (81.60%) | P = 0.075 |

Yes | 26 (78.80%) | 7 (21.20%) | 11 (32.40%) | 23 (67.60%) |

Outcomes | Day 1 | Day 7 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|

N | NLR < 10 | NLR > 11 | Unadjusted odds (P value) | aOR (P value) | N | NLR < 10 | NLR > 11 | Unadjusted odds (P value) | aOR (P value) | |

aOR: adjusted odds ratio; OR: odds ratio; NLR: neutrophil-to-lymphocyte ratio. | ||||||||||

Vent | 57 | 46 (81%) | 11 (19%) | OR 1.5 (0.6 - 3.5, P = 0.46) | aOR 1.5 (0.6 - 3.7, P = 0.33) | 55 | 36 (66%) | 19 (34%) | OR 3.3 (1.4 - 7.7, P = 0.008) | aOR 3.1 (1.2 - 8.4, P = 0.024) |

No vent | 110 | 95 (86%) | 15 (14%) | 80 | 69 (86%) | 11 (14%) | ||||

Upgrade | 53 | 42 (79%) | 11 (21%) | OR 1.7 (0.7 - 4.1, P = 0.30) | aOR 1.7 (0.7 - 4.1, P = 0.24) | 50 | 34 (68%) | 16 (32%) | OR 2.4 (1.0 - 5.4, P = 0.06) | aOR 2.3 (0.9 - 6.1, P = 0.08) |

No upgrade | 114 | 99 (87%) | 15 (13%) | 85 | 71 (84%) | 14 (16%) | ||||

Dialysis | 10 | 7 (70%) | 3 (30%) | OR 2.5 (0.6 - 10.3, P = 0.39) | aOR 2.5 (0.5 - 11.2, P = 0.25) | 8 | 6 (75%) | 2 (25%) | OR 1.2 (0.2 - 6.1, P = 0.81) | aOR 0.7 (0.1 - 5.7, P = 0.73) |

No dialysis | 157 | 134 (85%) | 23 (15%) | 127 | 99 (78%) | 28 (22%) | ||||

Died | 18 | 14 (78%) | 4 (22%) | OR 1.6 (0.5 - 5.5, P = 0.63) | aOR 1.9 (0.5 - 6.7, P = 0.30) | 18 | 12 (67%) | 6 (33%) | OR 11.0 (3.6 - 33.0, P < 0.0001) | aOR 11.1 (3.11 - 39.1, P < 0.0001) |

Alive | 149 | 127 (85%) | 22 (15%) | 117 | 99 (85%) | 18 (15%) |

Outcomes | Day 1 | Day 7 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|

N | LCR < 100 | LCR > 101 | Unadjusted odds (P value) | aOR (P value) | N | LCR < 100 | LCR > 101 | Unadjusted odds (P value) | aOR (P value) | |

aOR: adjusted odds ratio; OR: odds ratio; LCR: lymphocyte-to-C-reactive protein ratio. | ||||||||||

Vent | 60 | 17 (28%) | 43 (72%) | OR 2.5 (1.3 - 5.0, P = 0.01) | aOR 2.5 (1.3 - 5.0, P = 0.009) | 56 | 12 (21%) | 44 (78%) | OR 1.8 (0.8 - 4.0, P = 0.21) | aOR 1.06 (0.43 - 2.64, P = 0.89) |

No vent | 110 | 55 (50%) | 55 (50%) | 76 | 25 (33%) | 51 (68%) | ||||

Upgrade | 55 | 14 (26%) | 41 (75%) | OR 2.9 (1.47 - 6.1, P = 0.004) | aOR 3.1 (1.5 - 6.3, P = 0.003) | 50 | 10 (20%) | 40 (80%) | OR 2.0 (0.9 - 5.0, P = 0.16) | aOR 1.16 (0.46 - 2.96, P = 0.74) |

No upgrade | 115 | 58 (50%) | 57 (50%) | 82 | 27 (33%) | 55 (67%) | ||||

Dialysis | 10 | 3 (30%) | 7 (70%) | OR 1.8 (0.4 - 7.1, P = 0.63) | aOR 1.8 (0.4 - 8.0, P = 0.44) | 7 | 1 (14%) | 6 (86%) | OR 2.4 (0.3 - 21.0, P = 0.70) | aOR 3.7 (0.2 - 55.6, P = 0.34) |

No dialysis | 160 | 69 (43%) | 91 (57%) | 125 | 36 (29%) | 89 (71%) | ||||

Died | 20 | 10 (50%) | 10 (50%) | OR 0.71 (0.3 - 1.8, P = 0.62) | aOR 0.8 (0.3 - 2.0, P = 0.60) | 19 | 12 (63%) | 7 (37%) | OR 0.2 (0.06 - 0.47, P = 0.001) | aOR 0.1 (0.01 - 0.30, P < 0.0001) |

Alive | 150 | 62 (41%) | 88 (58%) | 113 | 25 (22%) | 88 (78%) |